Targeting interleukin-21 in immune-mediated pathologies

Curr Drug Targets. 2010 May;11(5):645-9. doi: 10.2174/138945010791011910.

Abstract

Interleukin (IL)-21, a cytokine mostly produced by activated CD4+ T cells, has been reported to play an important role in the tissue-damaging immune response in various organs. This pathogenic effect is strictly linked to the ability of IL-21 to control the functional activities of multiple immune and non-immune cells. For instance, IL-21 regulates the differentiation and function of effector CD4+ T helper cells; controls activation, proliferation, and survival of B cells and enhances the cytotoxic activity of CD8+ T cells and NK cells. IL-21 also inhibits the differentiation of inducible regulatory T cells (Tregs) and makes effector CD4+ T cells resistant to the Tregs-mediated immunesuppression. Additionally, IL-21 stimulates epithelial cells and fibroblasts to make chemokines and extracellular matrix proteases, respectively. Consistently, studies from various laboratories have documented the beneficial effect of IL-21 neutralization on the progression of inflammatory diseases in mice. Here we review the present knowledge on the expression and role of IL-21 in immune-mediated pathologies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Autoimmunity / genetics
  • Disease Models, Animal
  • Drug Delivery Systems / methods*
  • Humans
  • Immune System Diseases / drug therapy*
  • Immune System Diseases / metabolism
  • Interleukins / antagonists & inhibitors
  • Interleukins / genetics
  • Interleukins / metabolism*
  • Polymorphism, Genetic
  • Receptors, Interleukin-21 / genetics

Substances

  • Anti-Inflammatory Agents
  • Interleukins
  • Receptors, Interleukin-21
  • interleukin-21